"10.1371_journal.pone.0031784","plos one","2012-02-20T00:00:00Z","Andrea Harrer; Georg Pilz; Max Einhaeupl; Katrin Oppermann; Wolfgang Hitzl; Peter Wipfler; Johann Sellner; Stefan Golaszewski; Shahrzad Afazel; Elisabeth Haschke-Becher; Eugen Trinka; Joerg Kraus","Department of Neurology, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria; Central Laboratory, Christian-Doppler-Klinik, Paracelsus Medical University, Salzburg, Austria; Paracelsus Medical University, Research Office, Biostatistics, Salzburg, Austria","Conceived and designed the experiments: AH GP JK. Performed the experiments: AH ME KO. Analyzed the data: AH WH SG ET. Contributed reagents/materials/analysis tools: SA EHB ET. Wrote the paper: AH GP JS PW JK.","JS received consultation fees from Novartis and support for congress attendance from Merck Serono. ET has acted as a paid consultant to Eisai, Medtronics, Bial, and UCB. He has received research funding from UCB, Biogen-Idec, Sanofi-Aventis, and speakers' honoraria from Bial, Cyberonics, Desitin Pharma, Eisai, Gerot, BÃ¶hringer, Sanofi-Aventis, Medis, and UCB. JK received research funding from Bayer, Biogen-Idec, Genzyme, Merck-Serono, Novartis, and Sanofi- Aventis and personal compensation for consulting and presentations from Bayer, Biogen-Idec, Merck, Novartis, and Sanofi-Aventis. The research funding listed above did not apply to this study. This study was funded by Biogen Idec. Natalizumab is a product marketed by Biogen Idec as Tysabri, there are no further marketed products to declare and there are no patents or products in development. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2012","02","Andrea Harrer","AH",12,TRUE,3,3,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
